Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What's Your Number one Superhuman Film Made? - 2Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- 3The most effective method to Guarantee Simple Availability in Seniors' SUVs
- 4Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- 5Want to read more in 2026? Here's how to revive your love of books
- New study measures titanium in Apollo rock to uncover Moon’s early chemistry
- Picking the Right Home Machines: A Commonsense Aide
- Bullets in Luigi Mangione’s bag convinced police that he was UnitedHealthcare CEO killing suspect
- Police break up illegal chicken slaughter in Germany
- These men carry towers of birds through Mexico's streets. They say their tradition is dying out.
- Rights groups condemn Israel Police decision to ban Sudan Genocide protests nationwide
- An Ideal Getaway - Spots for Solo Travel
- 7 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
- Michael Jordan donates $10M to North Carolina medical center in honor of his mother
